Dynavax Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 408
- Market Cap
- $1.4B
- Introduction
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Sonoma Biotherapeutics Strengthens Leadership Team with Appointment of Rajesh Krishnan as Chief Technical Officer
Sonoma Biotherapeutics has appointed Rajesh Krishnan, Ph.D., as Chief Technical Officer to advance their engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases.
Dynavax Reports Strong Growth with HEPLISAV-B Revenue Up 26% in 2024, Advances Pipeline Programs
HEPLISAV-B achieved record net product revenue of $268.4 million in 2024, representing a 26% year-over-year growth, with market share reaching 44% in the U.S. hepatitis B vaccine market.
Goldman Sachs Downgrades Dynavax on Competitive Pressures in Shingles and Hepatitis B Markets
Goldman Sachs has downgraded Dynavax Technologies to Sell from Neutral, reducing price target to $12 amid growing competition in the shingles vaccine market and uncertainties around Z-1018 program.
HepB-CpG Vaccine Shows Superior Response in HIV Patients Non-Responsive to Traditional Hepatitis B Vaccine
A phase 3 trial showed HepB-CpG vaccine achieved superior seroprotection in HIV patients who did not respond to prior HepB-alum vaccination.